Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Woodstock,
Cheers! I enjoy yours too, especially those peppered with references to beautiful ladies: powdering their noses, engaging in interesting activities on Vancouver Island (if I remember correctly), etc. :-)
Have a good weekend!
EP
Enrico. My brother in law is one of these people that are essentially geniuses and make the likes of many look uneducated.
In essence as you convey, we have got along way to go yet. Anyone whom believes everything will go back to normal soon, is I'll informed.
Always enjoy your posts Enrico.
All the best.
Woodstock,
This will be a surprise but only to those who blindly follow whatever bombastic nonsense BoJo and Handjob decide to spout. It is clear that the vaccines, especially the cherished Oxford one, will not cope with the already existing variants and likely even less with any new ones.
The government's scientific advisors are in an impossible position: they have to peddle the "take your vaccine when invited to do so" line even though they are perfectly aware that the vaccines do not offer great protection from the newer (but already dominant) strains. They have to do it because telling people the truth would result in a minimal vaccine uptake, which would be even worse. If, on the other hand, people get vaccinated and so the government hits the % target, they'll be able to blame it on the new strains.
https://uk.yahoo.com/news/covid-cases-rising-areas-jonathan-van-tam-map-174346968.html
As I have posted a few times now, my brother in law has a degree in Biology from Oxford University. He is a man of few words but what he did say, was we will find it difficult to eradicate SARS covic 19 because genetically it is linked to the common cold. End of.
Furthermore Professor Neil Ferguson said recently unless we get the whole World population vaccinated, coronavirus will remain an ongoing problem.
Personally I am waiting for news on how many people are becoming ill with coronavirus after having the vaccine. I expect we will be in for a nasty surprise.
I'm with you on the COPD front Simmo, that's where the real long term value that pharmas in the respiratory space will be eyeing up as they look beyond Covid-19.
Covid-19 will become endemic, although there will be less of it in time hopefully.
correction, 230 estimated admitted rather than 220
I have just tried to dig a bit on take up rates for the trial. The NHS publishes statistics on hospital admissions.
https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/
Looking at the statistics for the University Hospitals Dorset Trust hospitals, there have been 346 Covid 19 admissions to the 3 hospitals in Poole, Bournemouth and Christchurch which make up the trust between 1st Feb and 21st Feb.
I have no idea about the sizes of the 3 hospitals, but let's assume they are all equal in size so we have about 220 admissions to Bournemouth and Christchurch between 1st and 21st Feb.
If we had 12 recruited until say a couple of days back, it roughly suggests about 5% of the patients agreed to take part in the trial based on the estimated hospital admissions here.
I just hope we have at least 10 to 15 hospitals already in the trial if the 5% take up rate might also apply across other sites. This is to stand a chance of completing the trial in the next few weeks in light of the falling hospital admission rates.
HarChris
'It would be much easier for SNG to just tell us in an rns! Anyone still talking to RM?'
I understand your frustration, but we will be RNS'd when the time is right. No CEO is expected to update shareholders on more than key milestone events, certainley not a daily tally on progress, much as that would sooth our impatience...
Something to keep in mind also - if someone claims to be 'talking to RM', they can just as easily infer negative news to serve their own agenda on boards such as these, it's not uncommon and can be highly damaging. Best to stick to RNS's as gospel and discount all rumours and heresay IMO.
Org.....remember your research......
15 years of research by Synairgen says this is an affective 'broad spectrum' anti-viral. It is therefore not reliant entirely on the Covid pandemic. Additionally as said, there is stockpiling.
Also remember that although deaths are reduced in the under 60s, 'long covid' is not. I know many relative youngsters who will now never manage a 'round of golf'......how would you consider that as a risk?
If someone is on good terms with their MP. It would be useful to ask a question in parliament or the lords on what number of patients have been enrolled so far in this critical priority trial
********************
It would be much easier for SNG to just tell us in an rns! Anyone still talking to RM?
The home trial results are arguably the most important of all. Yes the vast majority are ok and are able to 'sweat it out' but that isn't true in the over 70s and over 50s with serious comorbidities. As the age range goes even higher (80s+) the mortality rate gets extremely large. If the home trial results are compelling then certainly there would be no argument over early treatment for the most at risk groups.
It must be quite an administrative nightmare with all those trials running. There may be fewer new patients coming to hospital now and that will hopefully give the staff more time to talk them through the possible trials and try and get a high percentage signed up for one. Hopefully SNG-001 will prove increasingly popular.
Spinnaker
Isn't this the actual page for the trial? https://clinicaltrials.gov/ct2/show/NCT04732949
This one only has 3 hospitals listed. Bournemouth and Christchurch are of course not listed here.
Is that 12 for Bournemouth and Christchurch?
Great news.......extrapolated over the country....P3 should be filled shortly...
Good find Ferrari.
That’s not one of the 9 hospitals listed here...
https://clinicaltrials.gov/ct2/show/NCT04385095?term=Synairgen&draw=2&rank=1
So P3 must be filling reasonably quickly if they’ve had 12 recruits in a hospital late to be added to the list.
“ The team is taking part in further studies to see if existing treatments for other conditions or diseases or new drugs may be used to treat people with COVID-19.
Interferon beta ('IFN-beta') is part of the body's first line of defence against viruses. There is growing evidence that deficiency in IFN-beta production by the lung could explain 'at-risk' patient groups enhanced susceptibility to developing severe disease during respiratory viral infections such as SARS-CoV-2. Furthermore, SARS-CoV-2 seem to suppress its production as part of its strategy to evade our immune systems. Synairgen’s SNG001 is a formulation of IFN-beta-1a for direct delivery to the lungs via nebulisation. Phase I and II trial data have shown that SNG001 activates lung antiviral defences and has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to-date. The Royal Bournemouth Hospital is participating in SPRINTER (SG018) a placebo-controlled phase III trial of SNG001 who are hospitalised due to COVID-19 and require standard oxygen therapy. 12 patients have been enrolled so far.”